CD8A and neoplasm: Prophylactic mPhf3-DC vaccination, based on the mutated PHF3 peptide (mPHF3), can suppress ASB-XIV tumor progression by eliciting mPHF3-specific CD8+ T cell responses within the local tumor microenvironment, which mediate anti-tumor immunity.